Design Therapeutics (DSGN) Enterprise Value (2020 - 2026)
Design Therapeutics (DSGN) posted quarterly Enterprise Value of -$207.4 million for Q2 2026, up 4.11% year-over-year from -$199.2 million in Q2 2025, and up 6.92% on a QoQ basis from -$222.8 million in Q1 2026.
Design Therapeutics (DSGN) Enterprise Value (2020 - 2026) Analysis & Trends
Design Therapeutics has reported Enterprise Value for 7 years, with the latest figure at -$207.4 million in Q2 2026.
- Enterprise Value for Q2 2026 came in at -$207.4 million, up 4.11% year-over-year; the trailing twelve-month figure through Jun 2026 was -$207.4 million (up 4.11% YoY), and the FY2025 annual result was -$219.8 million, up 10.44% from the prior year.
- Enterprise Value improved to -$207.4 million in Q2 2026, from -$222.8 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$206.0 million in Q3 2025 and troughed at -$371.2 million in Q1 2022.
- A 5-year average of -$273.9 million and a median of -$265.9 million in 2024 frame the typical range for Enterprise Value.
- The widest annual swing landed in 2025, when Enterprise Value increased 18.93%; it then climbed 2.98% in 2026.
- A 5-year view of Enterprise Value shows it stood at -$330.4 million in 2022, then advanced by 14.71% to -$281.8 million in 2023, then advanced by 12.89% to -$245.5 million in 2024, then gained by 10.44% to -$219.8 million in 2025, then gained by 5.66% to -$207.4 million in 2026.
- Per Business Quant data, the three most recent Enterprise Value figures were -$207.4 million in Q2 2026, -$222.8 million in Q1 2026, and -$219.8 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Design Therapeutics | 928.06 Mn | 720.67 Mn | - | -207.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -207.40 Mn |
| Mar 31, 2026 | -222.82 Mn |
| Dec 31, 2025 | -219.85 Mn |
| Sep 30, 2025 | -205.97 Mn |
| Jun 30, 2025 | -216.28 Mn |
| Mar 31, 2025 | -229.67 Mn |
| Dec 31, 2024 | -245.48 Mn |
| Sep 30, 2024 | -254.07 Mn |
| Jun 30, 2024 | -261.02 Mn |
| Mar 31, 2024 | -270.69 Mn |
| Dec 31, 2023 | -281.80 Mn |
| Sep 30, 2023 | -290.94 Mn |
| Jun 30, 2023 | -303.09 Mn |
| Mar 31, 2023 | -315.39 Mn |
| Dec 31, 2022 | -330.39 Mn |
| Sep 30, 2022 | -344.23 Mn |
| Jun 30, 2022 | -359.38 Mn |
| Mar 31, 2022 | -371.22 Mn |
| Dec 31, 2021 | -384.06 Mn |
| Sep 30, 2021 | -357.77 Mn |